DIAGNOS Will Supply Its Artificial Intelligence Technology to the First Hypertensive Retina Screening Clinic in Saudi Arabia.

Brossard, Quebec, CANADA

BROSSARD, Quebec, April 16, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today it will supply its Artificial Intelligence technology to the first Hypertensive Retina Screening Clinic in Saudi Arabia with Kanhoor Medical Inc. (“Kanhoor”).

“We are delighted to open our first screening clinic for HBP in collaboration with DIAGNOS”, said the President of Kanhoor, Mr. Rashid AlMugait. He also added: “We encourage and support DIAGNOS in its endeavor as an AI pioneer.  We are pleased with this new hypertension application which will help us to provide an additional prevention service to our communities.”

“We are building on our long term relationship with Kanhoor. Together, we are making a difference in screening patients afflicted with Diabetes and Hypertension to reduce pain and stress to themselves and their families”, said Yves-Stephane Couture, Vice-President at DIAGNOS.

Our solution that we have explored recently is the use of artificial intelligence for reading and grading of hypertensive retinopathy.  It has been evaluated with sensitivity and specificity which is comparable to the manual reviews by specialists. “The software automatically elicits the severity level of the hypertensive retinopathy along with a recommendation for treatment referral. This information is relayed immediately to the doctor. The core objective of this project is to integrate AI effectively in the health care system, and to provide better quality health through early screening of chronic diseases by impacting and promoting prevention in a large population”, said Dr. Hadi Chakor, CMO at DIAGNOS.

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President
Tel: 450-678-8882 ext. 224

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.